Ferric maltol

Drug Profile

Ferric maltol

Alternative Names: Feraccru; Iron (III) maltol; ST-10; ST10-021

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Cambridge; University of London
  • Developer Shield Therapeutics
  • Class Antianaemics; Ferric compounds; Pyrones; Small molecules
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Iron deficiency anaemia

Most Recent Events

  • 10 Oct 2017 Shield Therapeutics completes enrolment in the phase III AEGIS-CKD trial in Iron deficiency anaemia in USA (NCT02968368)
  • 14 Mar 2017 Phase-I clinical trials in Iron deficiency anaemia (In children, In adolescents) in United Kingdom (PO) (NCT03181451)
  • 01 Nov 2016 Phase-III clinical trials in Iron deficiency anaemia (in pre-dialysis patients with chronic kidney disease) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top